Skip to main content
Premium Trial:

Request an Annual Quote

European AIDS Research Center to Test CombiMatrix siRNA against HIV

NEW YORK, June 30 - CombiMatrix is collaborating with the Retrovirology Laboratory irsiCaixa, an AIDS research center based in Barcelona, to test the efficacy of its pooled siRNA compounds against Human Immunodeficiency Virus, Type-1, the company said today.


CombiMatrix, an operating division of Acacia Research, said it would work with Bonaventura Clotet, chief of the AIDS unit at the University Hospital Germans Trias i Pujol, to validate its HIV gene-targeted siRNA pools. According to Amit Kumar, president and CEO of CombiMatrix, the company's approach, which targets all of the genes in a virus, "may provide a more powerful therapy than conventional approaches, and it should make it difficult for the virus to develop resistance."


The HIV project is CombiMatrix's second collaboration based on its siRNA platform, following an earlier collaboration based on SARS with the National Institute of Allergy and Infectious Diseases and the US Army Medical Research Institute of Infectious Diseases.


The company said it is targeting a number of other viruses with the siRNA platform, including HIV type 2, West Nile virus, human papillomavirus type 16, human herpes 8 (Kaposi's sarcoma), smallpox (variola), influenza virus A, influenza virus B, hepatitis C, and leishmania RNA virus.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.